Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
about
The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-AnalysisMeta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapyDiagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysisPrognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effectiveAssessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancerAccuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study.NEO adjuvant chemotherapy in breast cancer: What have we learned so far?The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewA Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyondAccuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancerDiagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIALImpact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.Neoadjuvant systemic treatment of breast cancer.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients.Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy.How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
P2860
Q26765032-2AF8487D-5EF9-4347-9FCB-149C362586C6Q27027281-4CC300DE-F5B4-4DCC-9EA9-4E95368F2924Q30315973-186EFD91-45CC-49E5-852E-FEA7D8CB3168Q30401252-4E554E47-A018-4EA8-B9F5-5751838F5251Q33593185-3B4D71EC-CECC-4E85-AEAA-BE7E8B8BEF05Q33620136-E1DDAE3D-57BA-4211-985B-F4BFAA0B5AE9Q33997699-09A1212A-AF76-4AA2-827F-8095CF8A0F9CQ34138174-230D27AC-A084-4DEE-A70A-3F2DE7EEDA89Q34566213-B0347FAB-EACA-4758-9319-A95460795549Q35239617-EFD5ABAC-8184-4EBE-9C0A-CC6BB0801191Q35657487-DA670589-19CA-4FF9-B7B9-DCB32408610DQ35928203-DA67583A-16DE-4FEA-8A48-A94191DD48E8Q36221963-8C0599EF-883D-4EE5-AACD-448024558B1FQ36762742-7684246E-5A99-4BCD-812A-B765179B7A13Q37734922-2BD76BCD-D2DA-4035-BAD2-A60DD3BFD550Q37845317-76FA73AC-3444-42AB-A7B3-DEA6AFD41A64Q38000076-D138566E-8F8B-40E4-8702-29300CBDB8F3Q38250247-0612FE46-EB86-473B-BDFF-5CE8CEBEB91FQ38439990-14129062-2943-4940-8AE0-B05696C6BBECQ39114881-C2E0C25D-3155-4A99-B804-29D2EC5C4F5FQ46561936-155A43EC-1F0B-4EB0-918D-A914761BC7ECQ46787048-7103F5C4-1D26-43BD-9489-C3798FEC970CQ46908078-46595319-96D0-4C66-928A-3BDC5AA7681CQ47270657-0B5C97EB-D580-4425-9499-C2FC082903ECQ53080309-CC079EA4-F34B-4410-BFD3-519CDC980F10
P2860
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@en
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@nl
type
label
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@en
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@nl
prefLabel
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@en
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@nl
P2093
P1476
Contrast enhanced magnetic res ...... hemotherapy for breast cancer.
@en
P2093
A V Desbiez-Bourcier
C Chapiron
L Brunereau
P304
P356
10.1016/J.EJSO.2004.07.024
P577
2004-12-01T00:00:00Z